Host Naresh Sunkara speaks with The company's CEO Yogev Debbi and scientific co-founder Avi Schroeder about how automation and AI are changing the development of RNA- and DNA-based medicines.
Mana.bio announced three additions to its board of directors and strategic advisors, alongside a poster presentation at the American Society of Gene & Cell Therapy 2026 Annual Meeting. The advisors have expertise in mRNA therapeutics, LNP delivery, business development, and strategic partnerships.
Mana.bio will present three new posters at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13–17 in New Orleans, LA.
Dr. Sepp Lorenzino has held roles at Intellia Therapeutics, Inc., Vertex Pharmaceuticals, Alnylam Pharmaceuticals, and Merck, and has overseen developments in genetic medicine and clinical development of complex modalities.
Mana.bio Co-founder and CEO Yogev Debbi shares insights on the company's mission, AI-driven LNP design, and the future of programmable medicine in a recent interview with AI Pressroom
Mana.bio is an AI-based drug delivery startup specializing in programmable drug delivery and gene therapy, with a focus on lipid nanoparticles (LNPs), RNA-based therapeutics, DNA therapeutics, and vaccines.
Mana.bio adds three leadership figures and plans to present machine learning-driven lipid nanoparticle (LNP) data for in vivo T-cell engineering at the ASGCT 2026 Annual Meeting. Thaminda Ramanayake joins its board, Michelle Lynn Hall becomes a board observer, and Guy Van Meter joins as strategic advisor.
Mana.bio launches Mina, an LLM-based AI agent built specifically for lipid nanoparticles. The company describes Mina as the world’s first LLM-powered agent for this field. It provides curated data, predictive modeling, and formulation insights intended to accelerate LNP discovery and RNA-based medicines.
Preview not available
Israeli biotech startup mana.bio launches AI-fueled programmable drug therapy
TechCrunchOct 2023
Israeli biotech startup Mana.bio launches a programmable drug treatment solution that uses an AI-driven approach involving liquid nanoparticles (LNP). The company had planned the launch for months and proceeds despite attacks in Israel over the preceding weekend.
Preview not available
Israeli biotech startup Mana.bio launches AI-fueled programmable drug therapy
TechCrunchOct 2023
Israeli biotech startup Mana.bio launches an AI-fueled programmable drug treatment solution, using AI to design lipid nanoparticles (LNPs) intended to enable programmable drug treatments. The company says it has planned the launch for months and moves ahead despite attacks in Israel the previous weekend.
Mana.bio raises $19.5 million in a seed round to advance its AI-driven lipid nanoparticle platform for RNA and gene therapies. Andreessen Horowitz Bio + Health, Base4 Capital, NFX, Technion, and LionBird co-lead the financing.